Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2011

01.11.2011 | Preclinical study

Role of CD200 expression in regulation of metastasis of EMT6 tumor cells in mice

verfasst von: Reginald M. Gorczynski, David A. Clark, Nuray Erin, Ismat Khatri

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Previous studies have confirmed that levels of CD200 expression on the cells of the transplantable EMT6 mouse breast cancer line are increased markedly during growth in immunocompetent mice, unlike the persistent low levels of expression observed in NOD-SCID.IL-2γr−/− mice or mice with generalized over-expression of a CD200 transgene (CD200tg mice). Faster tumor growth occurs in both of these latter mice, with decreased evidence for a host immune reaction in lymph nodes draining the tumor (DLN). We now report evidence for a role for CD200 expression (by the host and/or tumor cells) in increased seeding of tumor cells to DLN in immunocompromised (CD200tg or NOD-SCID.IL-2γr−/−) vs immunocompetent mice, by limiting dilution cloning of tumor cells from DLN (vs contralateral lymph nodes, CLN), using control and GFP-tagged EMT6 cells. Neutralization of expressed CD200 by anti-CD200mAbs decreased the tumor metastasis at the same time as increasing detection of cytotoxic anti-tumor immune cells in DLN. Infusion of either anti-CD4 to deplete T-effector cells, or anti-TGFβ antibody, increased metastasis to DLN, as did indeed the infusion of EMT6 cells selected for the loss of TGFβRII expression. It is concluded that the increased CD200 expression by breast cancer cells (and/or host tissue) may be an important variable involved in determining the risk of metastasis.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Geiger TR, Peeper DS (2009) Metastasis mechanisms. Biochim Biophys Acta 1796:293–308PubMed Geiger TR, Peeper DS (2009) Metastasis mechanisms. Biochim Biophys Acta 1796:293–308PubMed
2.
Zurück zum Zitat Bierie B, Moses HL (2009) Gain or loss of TGF beta signaling in mammary carcinoma cells can promote metastasis. Cell Cycle 8:3319–3327PubMedCrossRef Bierie B, Moses HL (2009) Gain or loss of TGF beta signaling in mammary carcinoma cells can promote metastasis. Cell Cycle 8:3319–3327PubMedCrossRef
3.
Zurück zum Zitat Pandit TS, Kennette W, MacKenzie L, Zhang GH, AlKatib W, Andrews J, Vantyghem SA, Ormond DG, Allan AL, Rodenhiser DI, Chambers AF, Tuck AB (2009) Lymphatic metastasis of breast cancer cells is associated with differential gene expression profiles that predict cancer stem cell-like properties and the ability to survive, establish and grow in a foreign environment. Int J Oncol 35:297–308PubMed Pandit TS, Kennette W, MacKenzie L, Zhang GH, AlKatib W, Andrews J, Vantyghem SA, Ormond DG, Allan AL, Rodenhiser DI, Chambers AF, Tuck AB (2009) Lymphatic metastasis of breast cancer cells is associated with differential gene expression profiles that predict cancer stem cell-like properties and the ability to survive, establish and grow in a foreign environment. Int J Oncol 35:297–308PubMed
4.
Zurück zum Zitat Pfeffer U, Romeo F, Noonan DM, Albini A (2009) Prediction of breast cancer metastasis by genomic profiling: where do we stand? Clin Exp Metastasis 26:547–558PubMedCrossRef Pfeffer U, Romeo F, Noonan DM, Albini A (2009) Prediction of breast cancer metastasis by genomic profiling: where do we stand? Clin Exp Metastasis 26:547–558PubMedCrossRef
5.
Zurück zum Zitat DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, Coussens LM (2009) CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16:91–102PubMedCrossRef DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, Coussens LM (2009) CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16:91–102PubMedCrossRef
6.
Zurück zum Zitat Valdivia-Silva JE, Franco-Barraza J, Silva ALE, DuPont G, Soldevila G, Meza I, Garcia-Zepeda EA (2009) Effect of pro-inflammatory cytokine stimulation on human breast cancer: Implications of chemokine receptor expression in cancer metastasis. Cancer Lett 283:176–185PubMedCrossRef Valdivia-Silva JE, Franco-Barraza J, Silva ALE, DuPont G, Soldevila G, Meza I, Garcia-Zepeda EA (2009) Effect of pro-inflammatory cytokine stimulation on human breast cancer: Implications of chemokine receptor expression in cancer metastasis. Cancer Lett 283:176–185PubMedCrossRef
7.
Zurück zum Zitat Pollard JW (2008) Macrophages define the invasive microenvironment in breast cancer. J Leukocyte Biol 84:623–630PubMedCrossRef Pollard JW (2008) Macrophages define the invasive microenvironment in breast cancer. J Leukocyte Biol 84:623–630PubMedCrossRef
8.
Zurück zum Zitat Walser TC, Ma XR, Kundu N, Dorsey R, Goloubeva O, Fulton AM (2007) Immune-mediated modulation of breast cancer growth and metastasis by the chemokine mig (CXCL9) in a murine model. J Immunother 30:490–498PubMedCrossRef Walser TC, Ma XR, Kundu N, Dorsey R, Goloubeva O, Fulton AM (2007) Immune-mediated modulation of breast cancer growth and metastasis by the chemokine mig (CXCL9) in a murine model. J Immunother 30:490–498PubMedCrossRef
9.
Zurück zum Zitat Ma XR, Norsworthy K, Kundu N, Rodgers WH, Gimotty PA, Goloubeva O, Lipsky M, Li Y, Holt D, Fulton A (2009) CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model. Mol Cancer Ther 8:490–498PubMedCrossRef Ma XR, Norsworthy K, Kundu N, Rodgers WH, Gimotty PA, Goloubeva O, Lipsky M, Li Y, Holt D, Fulton A (2009) CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model. Mol Cancer Ther 8:490–498PubMedCrossRef
10.
Zurück zum Zitat Takahashi M, Miyazaki H, Furihata M, Sakai H, Konakahara T, Watanabe M, Okada T (2009) Chemokine CCL2/MCP-1 negatively regulates metastasis in a highly bone marrow-metastatic mouse breast cancer model. Clin Exp Metastasis 26:817–828PubMedCrossRef Takahashi M, Miyazaki H, Furihata M, Sakai H, Konakahara T, Watanabe M, Okada T (2009) Chemokine CCL2/MCP-1 negatively regulates metastasis in a highly bone marrow-metastatic mouse breast cancer model. Clin Exp Metastasis 26:817–828PubMedCrossRef
12.
Zurück zum Zitat Huang B, Pan PY, Li QS, Sato AI, Levy DE, Bromberg J, Divino CM, Chen SH (2006) Gr-1(+)CD115(+) immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66:1123–1131PubMedCrossRef Huang B, Pan PY, Li QS, Sato AI, Levy DE, Bromberg J, Divino CM, Chen SH (2006) Gr-1(+)CD115(+) immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66:1123–1131PubMedCrossRef
13.
Zurück zum Zitat Yang L, Debusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP, Lin PC (2004) Expansion of myeloid immune suppressor GR1+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6:409–421PubMedCrossRef Yang L, Debusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP, Lin PC (2004) Expansion of myeloid immune suppressor GR1+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6:409–421PubMedCrossRef
14.
Zurück zum Zitat Lee NR, Song EK, Jang KY, Choi HN, Moon WS, Kwon K, Lee JH, Yim CY, Kwak JY (2008) Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis. Leuk Lymphoma 49:247–256PubMedCrossRef Lee NR, Song EK, Jang KY, Choi HN, Moon WS, Kwon K, Lee JH, Yim CY, Kwak JY (2008) Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis. Leuk Lymphoma 49:247–256PubMedCrossRef
15.
Zurück zum Zitat Qin FXF (2009) Dynamic behavior and function of Foxp3(+) regulatory T cells in tumor bearing host. Cell Mol Immunol 6:3–13PubMedCrossRef Qin FXF (2009) Dynamic behavior and function of Foxp3(+) regulatory T cells in tumor bearing host. Cell Mol Immunol 6:3–13PubMedCrossRef
16.
Zurück zum Zitat Bierie B, Moses HL (2010) Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev 21:49–59PubMedCrossRef Bierie B, Moses HL (2010) Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev 21:49–59PubMedCrossRef
17.
Zurück zum Zitat Chen T, Jackson CR, Link A, Markey MP, Colligan BM, Douglass LE, Pemberton JO, Deddens JA, Graff JR, Carter JH (2006) Int7G24A variant of transforming growth factor-beta receptor type 1 is associated with invasive breast cancer. Clin Cancer Res 12:392–397PubMedCrossRef Chen T, Jackson CR, Link A, Markey MP, Colligan BM, Douglass LE, Pemberton JO, Deddens JA, Graff JR, Carter JH (2006) Int7G24A variant of transforming growth factor-beta receptor type 1 is associated with invasive breast cancer. Clin Cancer Res 12:392–397PubMedCrossRef
18.
Zurück zum Zitat Yang L, Huang JH, Ren XB, Gorska AE, Chytil A, Aakre M, Carbone DP, Matrisian LM, Richmond A, Lin PC, Mosesl HL (2008) Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13:23–35PubMedCrossRef Yang L, Huang JH, Ren XB, Gorska AE, Chytil A, Aakre M, Carbone DP, Matrisian LM, Richmond A, Lin PC, Mosesl HL (2008) Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13:23–35PubMedCrossRef
19.
Zurück zum Zitat Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck R, Ryan S, Gotwals PJ, Koteliansky V, Arteaga CL (2002) Blockade of TGFb inhibits mammary tumor cell viability, migration and metastases. J Clin Invest 109:1551–1559PubMed Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck R, Ryan S, Gotwals PJ, Koteliansky V, Arteaga CL (2002) Blockade of TGFb inhibits mammary tumor cell viability, migration and metastases. J Clin Invest 109:1551–1559PubMed
20.
Zurück zum Zitat Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, Legouffe E, Moine P, Bourin P, Moos M, Corre J, Möhler T, De Vos J, Rossi JF, Goldschmidt H, Klein B (2006) CD200 is a new prognostic factor in multiple myeloma. Blood 108:4194–4197PubMedCrossRef Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, Legouffe E, Moine P, Bourin P, Moos M, Corre J, Möhler T, De Vos J, Rossi JF, Goldschmidt H, Klein B (2006) CD200 is a new prognostic factor in multiple myeloma. Blood 108:4194–4197PubMedCrossRef
21.
Zurück zum Zitat Petermann KB, Rozenberg GI, Zedek D, Groben P, McKinnon K, Buehler C, Kim WY, Shields JM, Penland S, Bear JE, Thomas NE, Serody JS, Sharpless NE (2007) CD200 is induced by ERK and is a potential therapeutic target in melanoma. J Clin Invest 117:3922–3929PubMed Petermann KB, Rozenberg GI, Zedek D, Groben P, McKinnon K, Buehler C, Kim WY, Shields JM, Penland S, Bear JE, Thomas NE, Serody JS, Sharpless NE (2007) CD200 is induced by ERK and is a potential therapeutic target in melanoma. J Clin Invest 117:3922–3929PubMed
22.
Zurück zum Zitat Moreaux J, Veyrune JL, Reme T, DeVos J, Klein B (2008) CD200: a putative therapeutic target in cancer. Biochem Biophys Res Commun 366:117–122PubMedCrossRef Moreaux J, Veyrune JL, Reme T, DeVos J, Klein B (2008) CD200: a putative therapeutic target in cancer. Biochem Biophys Res Commun 366:117–122PubMedCrossRef
23.
Zurück zum Zitat Siva A, Xin H, Qin F, Oltean D, Bowdish KS, Kretz-Rommel A (2008) Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200. Cancer Immunol Immunother 57:987–996PubMedCrossRef Siva A, Xin H, Qin F, Oltean D, Bowdish KS, Kretz-Rommel A (2008) Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200. Cancer Immunol Immunother 57:987–996PubMedCrossRef
24.
Zurück zum Zitat McWhirter JR, KretzRommel A, Saven A, Maruyama T, Potter KN, Mockridge CI, Ravey EP, Qin FH, Bowdish KS (2006) Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Natl Acad Sci USA 103:1041–1046PubMedCrossRef McWhirter JR, KretzRommel A, Saven A, Maruyama T, Potter KN, Mockridge CI, Ravey EP, Qin FH, Bowdish KS (2006) Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Natl Acad Sci USA 103:1041–1046PubMedCrossRef
25.
26.
Zurück zum Zitat Kawasaki BT, Mistree T, Hurt EM, Kalathur M, Farrar WL (2007) Co-expression of the tolerogenic glycoprotein, CD200, with markers for cancer stem cells. Biochem Biophys Res Commun 364:778–782PubMedCrossRef Kawasaki BT, Mistree T, Hurt EM, Kalathur M, Farrar WL (2007) Co-expression of the tolerogenic glycoprotein, CD200, with markers for cancer stem cells. Biochem Biophys Res Commun 364:778–782PubMedCrossRef
27.
Zurück zum Zitat Kawasaki BT, Hurt EM, Mistree T, Farrar WL (2008) Targeting cancer stem cells with phytochemicals. Mol Interv 8:174–184PubMedCrossRef Kawasaki BT, Hurt EM, Mistree T, Farrar WL (2008) Targeting cancer stem cells with phytochemicals. Mol Interv 8:174–184PubMedCrossRef
28.
Zurück zum Zitat Hoek RM, Ruuls SR, Murphy CA, Wright GJ, Goddard R, Zurawski SM, Blom B, Homola ME, Streit WJ, Brown MH, Barclay AN, Sedgwick JD (2000) Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 290:1768–1771PubMedCrossRef Hoek RM, Ruuls SR, Murphy CA, Wright GJ, Goddard R, Zurawski SM, Blom B, Homola ME, Streit WJ, Brown MH, Barclay AN, Sedgwick JD (2000) Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 290:1768–1771PubMedCrossRef
29.
Zurück zum Zitat Gorczynski RM, Chen Z, Diao J, Khatri I, Wong K, Yu K, Behnke J (2010) Breast cancer cell CD200 expression regulates immune response to EMT6 tumor cells in mice. Breast Cancer Res Treat 123:405–415PubMedCrossRef Gorczynski RM, Chen Z, Diao J, Khatri I, Wong K, Yu K, Behnke J (2010) Breast cancer cell CD200 expression regulates immune response to EMT6 tumor cells in mice. Breast Cancer Res Treat 123:405–415PubMedCrossRef
30.
Zurück zum Zitat Gorczynski RM, Chen ZQ, He W, Khatri I, Sun Y, Yu K, Boudakov I (2009) Expression of a CD200 transgene is necessary for induction but not maintenance of tolerance to cardiac and skin allografts. J Immunol 183:1560–1568PubMedCrossRef Gorczynski RM, Chen ZQ, He W, Khatri I, Sun Y, Yu K, Boudakov I (2009) Expression of a CD200 transgene is necessary for induction but not maintenance of tolerance to cardiac and skin allografts. J Immunol 183:1560–1568PubMedCrossRef
31.
Zurück zum Zitat Gorczynski RM (2005) CD200 and its receptors as targets for immunoregulation. Curr Opin Invest Drugs 6:483–488 Gorczynski RM (2005) CD200 and its receptors as targets for immunoregulation. Curr Opin Invest Drugs 6:483–488
32.
Zurück zum Zitat Gorczynski RM (2005) Thymocyte/splenocyte-derived CD4+CD25+ Treg stimulated by anti-CD200R2 derived dendritic cells suppress MLCs and skin graft rejection. Transplantation 81:1027–1034CrossRef Gorczynski RM (2005) Thymocyte/splenocyte-derived CD4+CD25+ Treg stimulated by anti-CD200R2 derived dendritic cells suppress MLCs and skin graft rejection. Transplantation 81:1027–1034CrossRef
33.
Zurück zum Zitat Boudakov I, Liu J, Fan N, Gulay P, Wong K, Gorczynski RM (2007) Mice lacking CD200R1 show absence of suppression of lipopolysaccharide-induced tumor necrosis factor-alpha and mixed leukocyte culture responses by CD200. Transplantation 84:251–257PubMedCrossRef Boudakov I, Liu J, Fan N, Gulay P, Wong K, Gorczynski RM (2007) Mice lacking CD200R1 show absence of suppression of lipopolysaccharide-induced tumor necrosis factor-alpha and mixed leukocyte culture responses by CD200. Transplantation 84:251–257PubMedCrossRef
34.
Zurück zum Zitat Andrews PD (2003) Aurora kinases: shining lights on the therapeutic horizon? Oncogene 24:5005–5015CrossRef Andrews PD (2003) Aurora kinases: shining lights on the therapeutic horizon? Oncogene 24:5005–5015CrossRef
35.
Zurück zum Zitat Snedecor GW, Cochrane WG (1971) Statistical methods, 6th edn. Iowa State University Press, Amres, pp 135–160 Snedecor GW, Cochrane WG (1971) Statistical methods, 6th edn. Iowa State University Press, Amres, pp 135–160
36.
Zurück zum Zitat Kalliomaki TM, McCallum G, Wells PG, Hill RP (2009) Progression and metastasis in a transgenic mouse breast cancer model: effects of exposure to in vivo hypoxia. Cancer Lett 282:98–108PubMedCrossRef Kalliomaki TM, McCallum G, Wells PG, Hill RP (2009) Progression and metastasis in a transgenic mouse breast cancer model: effects of exposure to in vivo hypoxia. Cancer Lett 282:98–108PubMedCrossRef
37.
Zurück zum Zitat Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, Aokage K, Saijo N, Nishiwaki Y, Gemma A, Kudoh S, Ochiai A (2008) Predominant infiltration of macrophages and CD8(+) T cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 113:1387–1395PubMedCrossRef Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, Aokage K, Saijo N, Nishiwaki Y, Gemma A, Kudoh S, Ochiai A (2008) Predominant infiltration of macrophages and CD8(+) T cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 113:1387–1395PubMedCrossRef
38.
Zurück zum Zitat Sica A, Allavena P, Mantovani A (2008) Cancer related inflammation: the macrophage connection. Cancer Lett 267:204–215PubMedCrossRef Sica A, Allavena P, Mantovani A (2008) Cancer related inflammation: the macrophage connection. Cancer Lett 267:204–215PubMedCrossRef
39.
Zurück zum Zitat Baumgartner J, Wilson C, Palmer B, Richter D, Banerjee A, McCarter M (2007) Melanoma induces immunosuppression by up-regulating FOXP3(+) regulatory T cells. J Surg Res 141:72–77PubMedCrossRef Baumgartner J, Wilson C, Palmer B, Richter D, Banerjee A, McCarter M (2007) Melanoma induces immunosuppression by up-regulating FOXP3(+) regulatory T cells. J Surg Res 141:72–77PubMedCrossRef
40.
Zurück zum Zitat Hilchey SP, De A, Rimsza LM, Bankert RB, Bernstein SH (2007) Follicular lymphoma intratumoral CD4(+)CD25(+)GITR(+) regulatory T cells potently suppress CD3/CD28-costimulated autologous and allogeneic CD8(+)CD25(−) and CD4(+)CD25(−) T cells. J Immunol 178:4051–4061PubMed Hilchey SP, De A, Rimsza LM, Bankert RB, Bernstein SH (2007) Follicular lymphoma intratumoral CD4(+)CD25(+)GITR(+) regulatory T cells potently suppress CD3/CD28-costimulated autologous and allogeneic CD8(+)CD25(−) and CD4(+)CD25(−) T cells. J Immunol 178:4051–4061PubMed
41.
Zurück zum Zitat Sakaguchi S (2004) Naturally arising CD4(+) regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22:531–562PubMedCrossRef Sakaguchi S (2004) Naturally arising CD4(+) regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22:531–562PubMedCrossRef
42.
Zurück zum Zitat Nagaraj S, Gabrilovich DI (2008) Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res 68:2561–2563PubMedCrossRef Nagaraj S, Gabrilovich DI (2008) Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res 68:2561–2563PubMedCrossRef
43.
Zurück zum Zitat Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58:49–59PubMedCrossRef Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58:49–59PubMedCrossRef
44.
Zurück zum Zitat Bierie B, Chung CH, Parker JS, Stover DG, Cheng N, Chytil A, Aakre M, Shyr Y, Moses HL (2009) Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer. J Clin Invest 119:1571–1582PubMedCrossRef Bierie B, Chung CH, Parker JS, Stover DG, Cheng N, Chytil A, Aakre M, Shyr Y, Moses HL (2009) Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer. J Clin Invest 119:1571–1582PubMedCrossRef
45.
Zurück zum Zitat Muraoka-Cook RS, Kurokawa H, Koh YS, Forbes JT, Roebuck LR, Barcellos-Hoff MH, Moody SE, Chodosh LA, Arteaga CL (2004) Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors. Cancer Res 64:9002–9011PubMedCrossRef Muraoka-Cook RS, Kurokawa H, Koh YS, Forbes JT, Roebuck LR, Barcellos-Hoff MH, Moody SE, Chodosh LA, Arteaga CL (2004) Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors. Cancer Res 64:9002–9011PubMedCrossRef
46.
Zurück zum Zitat Hess MR, Freschi M, Manzo T, Jachetti E, Degl’Innocenti E, Grioni M, Basso V, Bonini C, Simpson E, Mondino A, Bellone M (2010) Concomitant tumor and minor histocompatibility antigen-specific immunity initiate rejection and maintain remission from established spontaneous solid tumors. Cancer Res 70:3505CrossRef Hess MR, Freschi M, Manzo T, Jachetti E, Degl’Innocenti E, Grioni M, Basso V, Bonini C, Simpson E, Mondino A, Bellone M (2010) Concomitant tumor and minor histocompatibility antigen-specific immunity initiate rejection and maintain remission from established spontaneous solid tumors. Cancer Res 70:3505CrossRef
47.
Zurück zum Zitat Wong KK, Shaha S, Spaner D, Gorczynski RM (2009) Potential role for serum soluble CD200 in human Chronic Lymphocytic Leukemia. J Immunol 182:15 Wong KK, Shaha S, Spaner D, Gorczynski RM (2009) Potential role for serum soluble CD200 in human Chronic Lymphocytic Leukemia. J Immunol 182:15
48.
Zurück zum Zitat Ghebeh H, Barhoush E, Tulbah A, Elkum N, Al-Tweigeri T, Dermime S (2008) FOXP3+Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: implication for immunotherapy. BMC Cancer 8:57–68PubMedCrossRef Ghebeh H, Barhoush E, Tulbah A, Elkum N, Al-Tweigeri T, Dermime S (2008) FOXP3+Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: implication for immunotherapy. BMC Cancer 8:57–68PubMedCrossRef
Metadaten
Titel
Role of CD200 expression in regulation of metastasis of EMT6 tumor cells in mice
verfasst von
Reginald M. Gorczynski
David A. Clark
Nuray Erin
Ismat Khatri
Publikationsdatum
01.11.2011
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2011
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-1259-3

Weitere Artikel der Ausgabe 1/2011

Breast Cancer Research and Treatment 1/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.